Key result
High glucose increased monocyte adhesion to endothelial cells, which was reduced by 50% with IL-6 inhibition and by 40% with a PPARalpha agonist.
Why the study?
Does PPARalpha modulation and IL-6 inhibition reduce glucose-mediated monocyte-endothelial adhesion?
Does PPARalpha modulation and IL-6 inhibition reduce glucose-mediated monocyte-endothelial adhesion?
PPARalpha protects endothelial cells from glucose-mediated monocyte adhesion by regulating IL-6 production, highlighting a potential mechanism for early vascular inflammation in diabetes.
No immediate clinical implications in diabetes; leaves open whether IL-6 or PPARalpha modulation prevents vascular complications in vivo.
OBJECTIVE: We have previously reported increased monocyte adhesion to human aortic endothelial cells (HAECs) cultured in 25 mmol/L glucose (HG) compared with normal glucose (NG) (5.5 mmol/L). In this study, we explored mechanisms that contribute to increased monocyte adhesion by elevated glucose. METHODS AND RESULTS: We found that HAECs cultured in HG have increased production of the chemokine interleukin-6 (IL-6). We examined whether IL-6 directly modulated monocyte adhesion to EC. Inhibition of IL-6 using a neutralizing antibody significantly reduced glucose-mediated monocyte adhesion by 50%, and addition of IL-6 directly to human EC stimulated monocyte adhesion. PPARalpha has been reported to negatively regulate expression of IL-6 in vascular cells, so we examined PPARalpha-associated signaling in EC. A known PPARalpha agonist, Wy14,643, prevented glucose-mediated IL-6 production by EC and reduced glucose-mediated monocyte adhesion by 40%. HG-cultured HAEC had a 50% reduction in expression of PPARalpha compared with control EC. Primary aortic EC isolated from PPARalpha knockout (KO) mice showed increased monocyte adhesion compared with EC isolated from control mice. PPARalpha KO EC also had increased production of IL-6. Finally, we measured IL-6 levels in diabetic db/db mice and found significant 6-fold elevations in IL-6 levels in db/db EC. CONCLUSIONS: These data indicate that IL-6 production is increased in diabetes and contributes to early vascular inflammatory changes. PPARalpha protects EC from glucose-mediated monocyte adhesion, in part through regulation of IL-6 production.
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2004) studied Diabetes / Hyperglycemia. High glucose vs. Normal glucose (5.5 mmol/L) was evaluated on Monocyte adhesion and IL-6 production. High glucose increased monocyte adhesion to endothelial cells, which was reduced by 50% with IL-6 inhibition and by 40% with a PPARalpha agonist.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: